Nebido (Testosterone Undecanoate)

Testosterone undecanoate is a long‑acting ester that is hydrolyzed after intramuscular injection to release active testosterone. The testosterone binds to androgen receptors in target tissues, influencing gene expression that drives both androgenic and anabolic processes, thereby normalising hormonal balance and supporting male secondary sexual characteristics.

The specific dose and dosing interval of Nebido are determined by the prescribing clinician based on the patient’s age, weight, severity of testosterone deficiency, and treatment goals. Physicians typically follow approved labeling guidelines, and patients should follow the individualized regimen provided by their healthcare professional.

Nebido is not indicated for use in pregnant or breastfeeding individuals. Safety data are lacking, and testosterone therapy can affect fetal development and milk production. It is contraindicated in women who are or may become pregnant, and breastfeeding women should avoid exposure unless specifically advised by a qualified physician.

To order Nebido, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and necessary import documentation.

Nebido provides a long‑acting intramuscular formulation that requires fewer injections (typically every 10‑14 weeks) compared with shorter‑acting testosterone esters that may need weekly or bi‑weekly dosing. This extended dosing interval can improve patient convenience and adherence, while maintaining stable serum testosterone levels.

Nebido should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken. If temporary storage at ambient temperature is unavoidable for brief periods, the product should be returned to refrigeration as soon as possible to maintain stability.

Nebido is administered as an intramuscular injection into the gluteal muscle using a sterile technique. The injection is performed by a qualified healthcare professional. The volume per dose is 4 mL, containing 1000 mg of testosterone undecanoate, and the dosing schedule is set by the prescriber.

Serious risks include polycythemia, which can increase the chance of blood clots, cardiovascular events such as heart attack or stroke, severe allergic reactions (anaphylaxis), and potential worsening of prostate disease. Patients should be monitored regularly for hematocrit levels, cardiovascular health, and prostate status.

Nebido is contraindicated in individuals with known or suspected prostate cancer, breast cancer, severe untreated sleep apnea, uncontrolled heart failure, or those who have experienced a severe allergic reaction to testosterone undecanoate or any excipients in the formulation. It should also be avoided in women who are pregnant or breastfeeding.